文献速递血液净化与透析

美国血液透析患者矿物质代谢治疗策略趋势

Trends in Mineral Metabolism Treatment Strategies in Patients Receiving Hemodialysis in the United States.
PubMed 文献 · Clin J Am Soc Nephrol · 2020-10-12

该研究基于Dialysis Clinic, Inc. 23,549例新发血液透析成人,纵向评估维生素D甾醇、磷结合剂和西那卡塞处方。2006-2015年间,维生素D甾醇策略减少,无PTH调节剂策略和含西那卡塞策略增加,机构间实践差异增大。

要点

  • 透析起始时活性维生素D甾醇策略比例从15%降至5%。
  • 透析18个月后活性维生素D甾醇策略比例从52%降至34%。
  • 机构间使用不同策略的比值比从1.5-2倍增至2-3倍。

核心结论

  • 矿物质代谢管理逐渐减少维生素D甾醇策略,更多采用保守策略和含西那卡塞策略,实践差异增大,提示临床均势增加。

研究设计与样本

  • 在Dialysis Clinic, Inc.设施中启动血液透析的成人队列,共23,549例新发患者,纵向评估处方,按透析启动年份分层(2006-2008、2009-2011、2012-2015),使用混合效应多项逻辑回归估计中位比值比。

主要发现

  • 2006至2015年间,基于维生素D甾醇的策略下降,无PTH调节剂策略(单用磷结合剂或无用矿物质代谢药物)和含西那卡塞策略增加。
  • 透析启动时活性维生素D甾醇策略比例从15%(2006-2008)降至5%(2012-2015)。
  • 透析18个月后活性维生素D甾醇策略比例从52%(2006-2008)降至34%(2012-2015)。
  • 与参考策略(活性维生素D甾醇联合磷结合剂)相比,使用个体策略的比值比在2006-2008和2009-2011队列中机构间变异为1.5至2倍,在2012-2015队列中增至2至3倍。
  • 敏感性分析从首次PTH升高测量开始,结果相似。

临床怎么用

  • 临床实践中矿物质代谢管理策略趋于多样化,维生素D甾醇使用减少,西那卡塞和保守策略使用增加,机构间差异显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: With multiple medications indicated for mineral metabolism, dialysis providers can apply various strategies to achieve target phosphate and parathyroid hormone (PTH) levels. We describe common prescribing patterns and practice variation in mineral metabolism treatment strategies over the last decade. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a cohort of adults initiating hemodialysis at Dialysis Clinic, Inc. facilities, we assessed prescriptions of vitamin D sterols, phosphate binders, and cinacalcet longitudinally. To identify the influence of secular trends in clinical practice, we stratified the cohort by dialysis initiation year (2006-2008, 2009-2011, and 2012-2015). To measure practice variation, we estimated the median odds ratio for prescribing different mineral metabolism treatment strategies at 12 months post-dialysis initiation across facilities using mixed effects multinomial logistic regression. Sensitivity analyses evaluated strategies used after detection of first elevated PTH. RESULTS: Among 23,549 incident patients on hemodialysis, there was a decline in vitamin D sterol-based strategies and a corresponding increase in strategies without PTH-modifying agents (i.e., phosphate binders alone or no mineral metabolism medications) and cinacalcet-containing treatment strategies between 2006 and 2015. The proportion with active vitamin D sterol-based strategies at dialysis initiation decreased across cohorts: 15% (2006-2008) to 5% (2012-2015). The proportion with active vitamin D sterol-based strategies after 18 months of dialysis decreased across cohorts: 52% (2006-2008) to 34% (2012-2015). The odds of using individual strategies compared with reference (active vitamin D sterol with phosphate binder) varied from 1.5- to two-fold across facilities in 2006-2008 and 2009-2011 cohorts, and increased to two- to three-fold in the 2012-2015 cohort. Findings were similar in sensitivity analyses starting from first elevated PTH measurement. CONCLUSIONS: Over time, mineral metabolism management involved less use of vitamin D sterol-based strategies, greater use of both more conservative and cinacalcet-containing strategies, and increased practice variation, suggesting growing equipoise.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Hall R, Platt A, Wilson J, et al. Trends in Mineral Metabolism Treatment Strategies in Patients Receiving Hemodialysis in the United States. Clin J Am Soc Nephrol. 2020. PMID: 33046525. doi:10.2215/CJN.04350420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。